Liver Metastases News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic ... - Dove Medical Press



Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic ... 
Dove Medical Press
The meta-analysis demonstrated that there was no significant difference in liver tumor burden (odds ratio [OR] =1.51, 95% CI: 0.59?3.89, P=0.39) or tumor grade (OR =2.88, 95% CI: 0.92?9.04, P=0.07) among patients who underwent surgery and nonsurgical ...

 


Provectus updates on PV-10 in GI cancer; shares up 3% - Seeking Alpha



Provectus updates on PV-10 in GI cancer; shares up 3% 
Seeking Alpha
Four-site Phase 1 study in patients with hepatic lesions ongoing. 18 subjects treated to date, six with hepatocellular carcinoma (HCC), six with metastatic colorectal cancer (mCRC) and six with melanoma or breast, lung, ovarian or pancreatic cancer ...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL ... GlobeNewswire (press release)

all 2 news articles » 


New Extracellular Particle Could Prove Useful for Cancer Diagnosis, Monitoring - GenomeWeb



New Extracellular Particle Could Prove Useful for Cancer Diagnosis, Monitoring 
GenomeWeb
The smaller ones like to go to distant organs. Are they responsible for distant metastases? Liver is the number one organ where we find exomeres. What are they doing there?" One possibility, which Lyden said he and his colleagues are exploring in ...

 


MSI Status Shows No Effect on Metastatic Colorectal Cancer Prognosis - Curetoday.com



MSI Status Shows No Effect on Metastatic Colorectal Cancer Prognosis 
Curetoday.com
MSI Status Shows No Effect on Metastatic Colorectal Cancer Prognosis. Microsatellite instability (MSI) status appeared to have no association with outcomes in patients with liver metastases that spread from colorectal cancer (CRC), according to results ...

 


Extended Follow-Up Shows Benefit of Nivolumab in Advanced NSCLC - Cancer Network



Extended Follow-Up Shows Benefit of Nivolumab in Advanced NSCLC 
Cancer Network
There were 193 patients (23%) who had liver metastases at baseline. In these patients, there was again an OS benefit with nivolumab, with an HR of 0.68 (95% CI, 0.50?0.91). The 3-year OS rate was 8% with nivolumab and 2% with docetaxel in patients with ...

 


Selective Internal Radiotherapy Fails Again in mCRC - Medscape



Medscape
 
Selective Internal Radiotherapy Fails Again in mCRC 
Medscape
I'd like to discuss one of the studies that interested me at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO). This was the FOXFIRE study, led by a really good friend of mine, Prof Ricky Sharma, who spent a significant amount ...

 


Exercise Before Lung Cancer Surgery Greatly Reduces Complications - Oncology Nurse Advisor



Oncology Nurse Advisor
 
Exercise Before Lung Cancer Surgery Greatly Reduces Complications 
Oncology Nurse Advisor
Investigators found moderate-quality evidence demonstrating that pre-op exercise significantly reduced postoperative complication rates and hospital stay length. (HealthDay News) -- Preoperative exercise halves the rate of postoperative complications ...

 


Will Combination Therapies With Immunotherapy Become the New Standard of Care For NSCLC? - Targeted Oncology



Targeted Oncology
 
Will Combination Therapies With Immunotherapy Become the New Standard of Care For NSCLC? 
Targeted Oncology
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 016;17(11):1497-1508. Reck M. Primary PFS and safety ...

 


Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe - GlobeNewswire (press release)



Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe 
GlobeNewswire (press release)
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have performed the 500th PHP ...

and more » 


ASCO GU 2018: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic ... - UroToday



ASCO GU 2018: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic ... 
UroToday
At baseline, 46% of men had nodal metastases, 3% had liver metastases, and 3% had lung metastases. Post-treatment bone scans demonstrated 0, 1-4, 5-9, 10-20, and > 20 new bone lesions in 15%, 10%, 8%, 8%, and 18%, respectively; 10% had resolution of 1 ...

and more »